The Food and Drug Administration (FDA) restricts the use of immune treatments in stomach cancers

(MEDPAGE today) – The Food and Drug Administration has narrowed the indicators of Pembrolizumab (Keytruda) and Nivolumab (OPDIVO) at the intersection of gastric stomach and esophageal cancers, according to the messages sent to well -known drug makers. It was the agency …